Therapeutic Indications

Caplacizumab is indicated for:

Acquired thrombotic thrombocytopenic purpura (aTTP)

Irrespective of gender only Adults (18 - 65 years old)

Caplacizumab is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 10 mg once daily


Active ingredient Caplacizumab is contraindicated in the following cases: